|
Orforglipron shows modestly greater weight and HbA1c reductions than oral semaglutide, supporting its potential in type 2 diabetes.
|
 |
|
The agreement grants Knight Therapeutics rights to market the medicine for mycosis fungoides and Sézary syndrome subtypes.
|
|
|
Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.
|
|
|
This bet comes amid the strong industry buzz around the approval of Revolution Medicines’ OS-doubling pancreatic cancer treatment, Rasonque.
|
|
|
AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio.
|
|
